Gan & Lee Pharmaceuticals.
603087
株式のランク
#3011
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
株価
$10.03
時価総額
$5.99B
変化（1日）
-3.71%
変化（1年）
2.30%
国
CN
取引 Gan & Lee Pharmaceuticals. (603087)
カテゴリー
Healthcare
Gan & Lee Pharmaceuticals.（603087）の配当利回りの履歴
Gan & Lee Pharmaceuticals.（銘柄コード: 603087）の配当利回り（TTM）は2026時点で0です。
過去5年間の平均配当利回り: 0.92%
過去5年間の平均配当利回り: 0.92%
Gan & Lee Pharmaceuticals.（603087）の2013から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
| 年 | 配当利回り | 変化 |
|---|---|---|
| 2025 | 1.48% | -8.07% |
| 2024 | 1.61% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | 0.92% | 61.40% |
| 2021 | 0.57% | 111.11% |
| 2020 | 0.27% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | 0.01% | 0.00% |
| 2016 | 0.01% | 0.00% |
| 2015 | 0.01% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | 0.09% | 0.00% |
類似企業または競合他社の配当利回り（TTM）
| 企業 | 配当利回り | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 2.70% |
FR
|
|
| 0.00% |
JP
|
|
| 2.10% |
US
|
|
| 0.00% |
CH
|
